I am sure SI and team did not put in near 20 years of arduous work to sell out just as they are getting started in commercialisation and have not seen their biggest treatments through to approval also.
He would be feeling like his legs were cut out below him and I would also as an investor.
Maybe considered after HF and LBP were approved to feel fuller accomplishment in business and more real value for everyone holding shares.
To sell below a value $20 per share at this point of the company only just shifting into second gear and getting started to accelerate would be a crime.
Cell Therapy News/Articles, page-16706
-
- There are more pages in this discussion • 1,540 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |